

Safe Harbour



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Camlin Fine Sciences Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.








Q2 & H1 FY24 Performance Highlights

Q2 & H1FY24 Operational Highlights





4

Q2 & H1FY24 Operational Highlights


Key Highlights

- Despite difficult business environment, Company was able to achieve stable turnover of INR 4,059 Mn in the current quarter as compared to INR 4,196 MnQ1 FY 24 & INR 4,832 Mn in Q2 FY 23.
- > Blends business has gained traction and now it has increased by INR 390 Mn & INR 700 Mn as compared to Q1 FY 24 and Q2 FY 23 respectively.
- > Businesses in CFS NA & CFS Brazil have become EBITDA positive and will continue to grow further.
- Due to temporary closure of the Diphenol Plant, CFS Europe's turnover reduced to INR 422 Mn, precipitating in loss for the quarter of INR 264 Mn. In Q1 FY 24, turnover was INR 1,123 Mn and loss of INR 32 mn, while in Q2 FY 23, turnover was INR 1,552 Mn and profit of INR 296 mn. During the quarter before temporary shutdown, the Diphenol plant produced HQ 193 MT & CAT 268 MT, as compared to Q1 FY 24 of HQ 1,165 MT & CAT 1,518 MT & corresponding Q2 FY 23 production was HQ 1,157 MT & CAT 1,296 MT.
- > Vanillin scale up expected to improve in the coming half year with successful progress in customers approvals.
- Company has commenced production of Ethyl Vanillin by campaign at our Composite Vanillin Plant at Dahej.
- > Gross margins were impacted due to softening of prices , 367 bps as compared to Q1 FY 24 and 575 bps as compared to Q2 FY 23
- Net debt was at INR 5,645 Mn as on September 30, 2023 as compared to INR 6,804 Mn as on March 31, 2023, especially due to conversion of FCCB into equity



••• Operational Revenue Break-up






On Consolidated Basis *Excluding Other Products

•••• Regional Highlights





On Consolidated Basis

• • •

Consolidated Profit & Loss Statement



Particulars (Rs. In Mn)	Q2 FY24	Q2 FY23	ϒοϒ	Q1 FY24	ဝ၀ဝ	H1 FY24	H1 FY23
Revenue from Operation	4,058.8	4,832.5	-16.0%	4,196.0	-3.3%	8,254.8	8,670.2
Raw material consumption	2,236.1	2,384.6		2,157.8		4,393.9	4,166.0
Employee Cost	432.4	389.6		438.5		870.9	800.8
Other expenses	1,139.0	1,506.2		1,212.6		2,351.6	2,660.8
EBITDA	251.3	552.1	-54.5%	387.1	-35.1%	638.4	1,042.7
EBITDA Margins (%)	6.2%	11.4%		9.2%		7.7%	12.0%
Adjusted EBITDA*	316.7	552.1	-42.6%	446.9	-29.1%	763.7	1,047.5
Adjusted EBITDA Margins (%)	7.8%	11.4%		10.7%		9.3%	12.1%
Other Income	17.6	28.8		63.7		81.3	14.7
Depreciation	192.0	140.2		187.8		379.8	284.0
Finance cost	197.8	184.5		102.2		300.0	371.8
Exceptional Item	-	-		-		-	-
РВТ	-120.9	256.1	nm	160.8	nm	39.9	401.6
Tax	87.4	157.4		40.6		128.0	266.9
ΡΑΤ	-208.3	98.7	nm	120.2	nm	-88.1	134.7
PAT Margins (%)	-5.1%	2.0%		2.9%		-1.1%	1.6%
Diluted EPS (in Rs.)	-1.16	0.93		0.94		-0.2	1.27

*EBITDA is adjusted for FX gain / loss

• • •

Standalone Profit & Loss Statement



Particulars (Rs. In Mn)	Q2 FY24	Q2 FY23	ΥοΥ	Q1 FY24	ဝ၀ဝ	H1 FY24	H1 FY23
Revenue from Operation	2,062.1	2,431.5	-15.2%	1,611.1	28.0%	3,673.3	3,985.9
Raw material consumption	1,078.2	1,185.1		632.2		1,710.4	1,968.1
Employee Cost	177.0	129.5		154.8		331.8	269.6
Other expenses	593.4	694.8		573.2		1,162.2	1,169.8
EBITDA	213.5	422.1	-49.4%	250.9	-14.9%	468.9	578.4
EBITDA Margins (%)	10.4%	17.4%		15.58%		12.8%	14.5%
Adjusted EBITDA*	213.5	422.1	-49.4%	255.4	-16.4%	468.9	578.4
Adjusted EBITDA Margins (%)	10.4%	17.4%		15.8%		12.8%	14.5%
Other Income	56.3	121.0		60.1		112.0	244.8
Depreciation	124.1	72.9		118.0		242.1	145.7
Finance cost	151.0	163.3		120.5		271.5	319.1
РВТ	-5.2	306.9		72.6		67.4	358.5
Tax	9.3	120.1		14.8		24.1	118.9
ΡΑΤ	-14.6	186.8	nm	57.8	nm	43.2	239.6
PAT Margins (%)	-0.7%	7.7%		3.6%		1.2%	6.0%
Diluted EPS (in Rs.)	-0.1	1.3		0.3		0.3	1.6

*EBITDA is adjusted for FX gain / loss

Consolidated Balance Sheet



Particulars (Rs. In Mn)	Sep - 23	Mar - 23	Particulars (Rs. In Mn)	Sep - 23	Mar - 23
Equity			Non-Current assets		
Equity Share Capital	167.5	157.1	Property, Plant and Equipment	7,338.6	7,525.2
Other Equity	9,262.8	8,036.6	Capital Work-In-Progress	497.0	408.4
Minority interest	-7.6	47.1	Right use of assets	457.3	410.8
Total Equity	9,422.7	8,240.8	Goodwill	527.9	527.9
Non-Current Liabilities			Other Intangible Assets	104.5	112.2
Financial Liabilities			Intangible assets under development	32.8	21.9
Borrowings	3,512.2	4,081.0	Financial Assets		
Lease Liabilities	178.5	143.3	Investments	78.8	79.6
Other Liabilities	3.7	3.0	Other Financial Assets	145.7	166.2
Provisions	47.7	48.1	Deferred tax assets	288.4	299.8
Deferred Tax Liabilities (Net)	156.3	151.0	Income Tax Assets	151.8	125.8
Other non-current liabilities	3.7	3.9	Other Non-Current Assets	24.6	45.1
Total Non-Current Liabilities			Total Non-Current Assets	9,646.5	9,722.8
	3,902.0	4,430.3	Current Assets		
Current Liabilities			Inventories	5,906.9	5,681.4
Financial Liabilities			Financial Assets		
Borrowings	3,149.8	3,714.9	Trade Receivables	2,405.8	3,045.9
Lease Liabilities	85.9	66.3	Cash and Cash Equivalents	924.2	937.4
Trade Payables	2,403.7	2,883.5	Bank Balances	88.7	54.9
Other Financial Liabilities	644.1	639.2	Loans	100.8	101.4
Other Current Liabilities	365.1	378.6	Other Financial Assets	57.6	41.4
Provisions	94.5	104.9	Other Current Assets	985.6	995.1
Current tax liabilities (Net)	69.1	142.5	Assets held for sale	20.7	20.7
Total Current Liabilities	6,812.2	7,929.9	Total Current Assets	10,469.7	10,857.5
Total Equity and Liabilities	20,136.9	20,601.0	Total Assets	20,136.9	20,601.0

• • •

Consolidated Cash Flow Statement




Particulars (Rs. In mn)	Sep - 23	Sep - 22
Net Profit Before Tax	39.9	401.6
Adjustments for: Non-Cash Items / Other Investment or Financial Items	742.9	607.8
Operating profit before working capital changes	782.8	1,009.4
Changes in working capital	-128.2	-739.2
Cash generated from Operations	654.6	270.2
Direct taxes paid (net of refund)	-217.5	-109.1
Net Cash from Operating Activities	437.1	161.0
Net Cash from Investing Activities	-290.8	-1,010.9
Net Cash from Financing Activities	-159.5	634.1
Net Decrease in Cash and Cash equivalents	-13.2	-215.8
Add: Cash & Cash equivalents at the beginning of the period	937.4	1,078.1
Cash & Cash equivalents at the end of the period	924.2	862.4




Touching Billions of Lives Daily

Vertical Integration | Green Chemistry | R&D | Innovative Solutions



••• Company Overview





Global Footprint






located across multiple continents to cater to the needs of customers.

Manufacturing Strength

- > Leveraging the power of vertical integration, CFS possesses state-of-the-art facilities that enable large-scale production while upholding rigorous quality benchmarks
- > Existing facilities across four continents have a total capacity of 61,000+ MT
- > The backbone of vertically integrated production coupled with R&D and Application Laboratory efforts has been the key driver to reach out to diverse industries and numerous markets



Map not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

Headquarter

CFS Dresen,

Mexico

CFS Britec,

Guatemala



Sales office

14

••• Product Highlights



		FY23	Sales Mix%	Key Products	End User Industries	Key Brands
Shelf-Life	Straights		28%	 > TBHQ > BHA > Ascorbyl palmitate (ASP) 	 Pet Food Animal Feed Mills Livestock Nutrition Biodiesel Food & Beverages Aquaculture Fish Meal Rendering 	NaSure Extending Shelf Life Naturally
Solutions		31%	 200+ custom formulations, encompassing both traditional and natural solutions (forward-integrated antioxidant blends) 	 These formulations are specifically tailored to meet the diverse needs of the industry Aim to increase focus on high-value blends and additives 	Xtendra shelf life solutions	
Performan Chemicals			41%	 > HQ derivatives products like Chloranil, MEHQ, HQEE, TBHQ, PDMB, CME, > CT derivative products like 4 TBC, Guethol, Veratrole, Guaiacol, 1, 2MDB 	 Petrochemicals Dyes & Pigments Agrochemicals Polymers Printing Inks 	Dinamic Performance Chemicals
Aroma Ing	redients		0%	› Vanillin, Ethyl Vanillin and Vanillin ex- clove (adorr™)	 Food & Beverages Chocolate & Confectionary Pharmaceutical Perfume & Incense Flavors & Fragrance Bakery Personal Care Animal Feed 	adiger (Sensory sciences Chinethyl Hydroquinone (DMHQ)
Health & W	/ellness		0%	 Omega-3 fatty acids from micro-algae 	 Pharmaceutical & > Pet Food Nutraceuticals > Food and Beverages Dietary Supplement > Animal Feed Functional Foods 	EIGSUS EIGSUS OMEGA 20 20% DHA from algal biomas

Vertical

Vertical Integration | Green Chemistry | R&D | Innovative Solutions

Application

laboratories

India | Italy | Brazil | USA | Mexico





Backward Integrated through Italy & Dahej Facilities for captive consumption and for **Downstream Progression**

From Source, to Quality Solutions

- Efforts in both organic and inorganic expansions, showcases company's commitment to fortifying position in the market
- Strategic focus on captive consumption ensures utilization of raw materials for downstream products
- Strategic forward integration into Blends and Vanillin swings company's business model to high-value additives / solutions

Green Chemistry

Green chemistry goals at CFS

R&D

India | Italy | Mexico

centres

- Promoting use of energy-efficient processes
- Minimizing the generation of waste during chemical
- Synthesis Supporting end consumers clean-label demands

The integration of green chemistry encompasses the following

- Finding ways to adopt new ecosystems to include new materials, processes, and alternatives to nature's finite resources like briquette instead of coal as an energy source
- · Solvent, one of the largest waste components in the manufacturing process is recovered, purified and repurposed for manufacturing process
- · Through fermentation technology, company work on developing products like nutritional lipids in a sustainable form for the food and beverage, pet food, and animal nutrition industries

Exploring new horizons

- Add value to existing products
- Integrate customized, enhanced applications
- Develop derivatives for Hydroguinone and Catechol
- Improve current process for efficient manufacturing and better products
- Develop new products for a more comprehensive and robust portfolio

Innovative Solution

R&D




Expanding Innovative Solutions

Building a purposeful portfolio

- Establishing CFS as a strong player across food and feed protection, safety solutions, sensory sciences, functional excellence, performance chemicals, health and nutrition
- Vertically integrated across the value chain, giving customers complete control
- An extensive global footprint enabling us to make a localized impact through enhanced accessibility, customer convenience, and a wide array of sustainable solutions

Integration Chain






¹ Ascorbyl Palmitate is not a part of HQ / Catechol value-chain and is manufactured from ascorbic acid





As a responsible corporate, CFS understand the importance of Environmental, Social and Governance (ESG) practices in conducting business ethically. Company's commitment to ESG extends beyond compliance with regulations and laws. Company aims to minimize environmental impact, promote social responsibility and ensure good governance.





Board of Directors



Name	Profile
Ashish Dandekar Chairman & Managing Director	 Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing Holds a BA in Economics and Management studies from Temple University, USA
Nirmal Momaya Managing Director	 Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy Founder at Pagoda Advisors Pvt. Ltd, with a focus on consulting for various businesses as well as advising CFS on important business and strategic matters since 2009
Arjun Dukane Executive Director - Technical	 Chemical Engineer with over three decades of experience in the chemical industry Has been associated with CFS for more than 14 years
Harsha Raghavan Non-Executive Non-Independent Director	 Managing Partner of Convergent Finance LLP and ex-founding MD & CEO of Fairbridge Capital (a Fairfax Company) Holds an MBA & MSc in industrial engineering from Stanford University and a B.A from University of California, Berkeley
Anagha Dandekar Non-Executive Non-Independent Director	 President & co-founder of Hardware Renaissance, a manufacturer of handcrafted door hardware and accessories Holds an MBA in Finance from the University of South Carolina, USA
Amol Shah Independent Director	 Managing Director of the MJ Group with over three decades of experience in the industry covering human healthcare, flavors/fragrances compounds, plant protection, and water treatment chemicals Holds an MBA from the University of Southern California and a Bachelor's in Engineering from the University of Kent
Joseph Conrad D'souza Independent Director	 Erstwhile Member of Executive Management and Chief Investor Relations Officer of HDFC Ltd Board member of various HDFC group companies, Chalet Hotels, Nations Trust Bank, and Asianet Satellite Communications Ltd Holds an M.com from Mumbai University and an MBA from South Gujarat University
Pradip Kanakia Independent Director	 Qualified Chartered Accountant (both England, Wales and India) with over three decades of experience Held leadership position in PWC & KPMG, and currently Board member of Torrent Gas and Fable Fintech
Sutapa Banerjee Independent Director	 Gold medalist in economics from XLRI India, and an Economics honors graduate from Presidency College Kolkata Over two decades of experience in the financial services industry and currently serves as an Independent Director on the boards of several companies
Mahabaleshwar Palekar Independent Director	 Over two decades of experience with corporates in India (Polychem & Atul) and MNCs (Unilever India and Rhodia India) Chemical engineer with a degree from the Institute of Chemical Technology (ICT) in Mumbai, India





Independent directors

• • •

Senior Management Team



Name	› Profile
Ashish Dandekar Chairman & Managing Director	 Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing Holds a BA in Economics and Management studies from Temple University, USA
Nirmal Momaya Managing Director	 Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy Founder at Pagoda Advisors Pvt. Ltd, with a focus on consulting for various businesses as well as advising CFS on important business and strategic matters since 2009
Arjun Dukane Executive Director- Technical	 Chemical Engineer with over three decades of experience in the chemical industry Has been associated with CFS for more than 14 years
Santosh Parab Chief Financial Officer	 Over three decades of experience working across various accounting firms Previously worked at B.K. Khare & Co, an Indian accounting firm Qualified Chartered Accountant with a Bachelor's degree in commerce
Eric Santos Vice President	 Over two decades of industry experience, previously worked as a commercial director at Solvay S.A. Holds a Bachelor's degree in chemistry
Massimo Cupello Head - Italy operations	 Over three decades of experience in varied industries including food chocolate and private equity Previously worked at Ferrero Chocolate, Unopiu (Sinergo & CCP) in Europe Holds an MBA in International Business and a Bachelor's degree in Science
Jose Arturo Paulin Head - Mexico operations	 Over two decades of experience in the feed market (premix, feed additives, pet food, and rendering) Previously worked at Trouw Nutrition and Kemin Inc in Mexico Qualifed agriculture engineer
Jennifer Igou Head - USA operations	 Over two decades of experience in food and pet-food space particularly in anti-oxidants & Hydrocolloids Previously worked at Kemin Inc. USA & FMC Holds a Bachelor's degree in Chemistry and Biology with an emphasis in Biomedicine



••• Way Forward



Shelf-Life Solutions

- Maintaining market leadership for Antioxidants
- Increasing focus on high margin blends and additives. These formulations are specifically tailored to meet the diverse needs of the industry
- Widen portfolio to provide a comprehensive solution for the food, pet food, biodiesel, livestock and aquaculture industries

Performance Chemicals

- Aim to expand Diphenol chain, specifically focusing on expanding downstream products
- Introduction of new products like CME, Chloranil, Napthol etc.
- Increasing manufacturing capacity of existing products through debottlenecking (MEHQ)
- Aim to give a major impetus to the 'Make in India' initiative by launching exciting products

Aroma Ingredients

- Introduce specialized and customized products within the vanillin range, catering to diverse application needs
- Actively pursuing an expansion in the aroma industry
- The production of Ethyl Vanillin and vanillin ex-clove (natural vanillin) completes comprehensive range of Vanillin offerings for the market
- Poised to achieve optimum capacity utilization in coming years

Health and Wellness


- Improving process stability, laying the framework for expanding into new markets, and investigating potential applications in existing ones are currently top priorities for Biosus[™] DHA
- Aim is to establish a formidable presence in prominent markets such as Europe and the United States.














Operational Revenue Break-Up





Shelf-Life Extension (Rs. In Mn)




Blends (Rs. In Mn)

Total Shelf-Life Solution (Rs. In Mn)






Performance Chemicals (Rs. In Mn)



Aroma Chemicals (Rs. In Mn)








*Excluding Other Products

•••• Regional Highlights





CFS India (Rs. In Mn)



CFS Mexico (Rs. In Mn)

CFS Europe (Rs. In Mn)








CFS Brazil (Rs. In Mn)



CFS North America (Rs. In Mn)








Historical Financial Highlights







Thank You!



Camlin Fine Sciences Ltd. CIN - L74100MH1993PLCO75361 Mr. Santosh Parab- CFO Email - <u>santosh.parab@camlinfs.com</u> www.camlinfs.com

$\mathbf{SGA}^{\mathtt{Strategic Growth Advisors}}$

Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Shaily Patwa Email <u>- shrikant.sangani@sgapl.net / shaily.p@sgapl.net</u> Mobile No - 9619595686 / 9819494608 www.sgapl.net